David S. Burgess - Publications, H-index & Citations

David S. Burgess

western sydney university

37H指数

181论文数

4.4K被引数

收录论文 46

发表时间

1681: EVALUATING CLINICAL OUTCOMES OF GRAM-NEGATIVE BACTEREMIA AND PRESENCE OF ID CONSULT 1681: 评估革兰阴性菌血症的临床结局及ID会诊的存在

Critical Care Medicine

IF6

2026-03-03

PREAI

Oliver, Emily; Burgess, David

Impact of a multistep urinary tract infection-focused disease state stewardship initiative on the treatment of asymptomatic urinary presentations: a retrospective cohort study 多步骤针对尿路感染疾病的疾病状态管理倡议对无症状性尿路表现治疗的影响：一项回顾性队列研究

Therapeutic Advances in Infectious Disease

IF3.4

2025-11-10

OAAI

Christian Tyler Pitcock; Danielle Casaus; Sarah E. Garvey; Katie Ruf; Donna R. Burgess; Jeremy D. VanHoose; David S. Burgess; Ryan Mynatt; Armaghan-e-Rehman Mansoor; Nicholas Van Sickels; Mitu Karki Maskey; Thein Myint; Aric Schadler; Katie L. Wallace

Novel predictors of major adverse cardiovascular events in patients with Takotsubo cardiomyopathy: a contemporary analysis

Internal Medicine Journal

IF1.5

2025-10-01

PREAI

Quader, Tameem; Jirjis, Adeeb; Khanna, Shaun; Gu, Kennith; Bhat, Aditya; Chen, Henry; Gan, Gary; Ying, Victoria; Burgess, David; Nerlekar, Nitesh; Ghelani, Dhaval; Eshoo, Suzanne

Evaluation of High-dose Daptomycin in Children With Methicillin-resistant Staphylococcus aureus Bacteremia: A Case Series 高剂量达托霉素在耐甲氧西林金黄色葡萄球菌菌血症儿童中的评价：一个病例系列

PEDIATRIC INFECTIOUS DISEASE JOURNAL

IF2.2

2025-10-01

PREAI

Olney, Katie B.; Pai, Manjunath P.; Stadler, Laura P.; Burgess, David S.

Risk of Treatment Failure in Outpatient Parenteral Antimicrobial Therapy From an Academic Medical Center in Kentucky 肯塔基州某学术医学中心门诊抗菌药物治疗失败的风险

Open Forum Infectious Diseases

IF3.8

2025-08-01

OAAI

Kaylee Worsham Behal; Bobbi Jo Stoner; Aric Schadler; Donna Burgess; David S Burgess; Ryan P Mynatt

Optimizing cefazolin dosing for central nervous system infections: insights from population pharmacokinetics and Monte Carlo simulations 优化头孢唑林剂量用于中枢神经系统感染：群体药代动力学和蒙特卡洛模拟的见解

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2025-05-20

OAAI

Pitcock, C. Tyler; Burgess, David S.; Olney, Katie B.

Comparing the activity of broad-spectrum beta-lactams in combination with aminoglycosides against VIM-producing Enterobacteriaceae

MICROBIOLOGY SPECTRUM

IF3.8

2024-10-03

OAAI

Clark, Justin A.; Burgess, David S.

Acute Kidney Injury Associated with Area under the Curve versus Trough Monitoring of Vancomycin in Obese Patients

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2022-01-18

OAAI

D'Amico, Heather; Wallace, Katie L.; Burgess, Donna; Burgess, David S.; Cotner, Sarah; Mynatt, Ryan; Li, Nannan; Stromberg, Arnold; VanHoose, Jeremy

Efficacy and safety of vancomycin loading doses in critically ill patients with methicillin-resistant Staphylococcus aureus infection 万古霉素负荷剂量对耐甲氧西林金黄色葡萄球菌感染危重患者的疗效和安全性

THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE

IF3.4

2021-03-30

OAAI

Flannery, Alexander H.; Wallace, Katie L.; Rhudy, Christian N.; Olmsted, Allison S.; Minrath, Rachel C.; Pope, Stuart M.; Cook, Aaron M.; Burgess, David S.; Morris, Peter E.

Evaluation of a Disease State Stewardship Intervention for Urinary Tract Infections at an Academic Medical Center

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

IF3

2020-11-02

OAAI

Xhemali, Xhilda; Forster, Derek; Clemons, Bryant; Cotner, Sarah; VanHoose, Jeremy; Burgess, Donna; Burgess, David; Myint, Thein; Maskey, Mitu Karki; Wallace, Katie

Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance

THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE

IF3.4

2020-09-04

OAAI

Clark, Justin A.; Burgess, David S.

Focusing the Lens on the CAMERA Concepts: Early Combination β-Lactam and Vancomycin Therapy in Methicillin-Resistant Staphylococcus aureus Bacteremia 将镜头聚焦在相机概念上: 耐甲氧西林金黄色葡萄球菌菌血症的早期 β-内酰胺和万古霉素联合治疗

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2020-06-23

OAAI

Wilsey, H. Andrew; Burgess, Donna R.; Burgess, David S.

Polymyxin B Etest® compared with gold-standard broth microdilution in carbapenem-resistant Enterobacteriaceae exhibiting a wide range of polymyxin B MICs

CLINICAL MICROBIOLOGY AND INFECTION

IF8.5

2019-01-01

OAAI

Kulengowski, B.; Ribes, J. A.; Burgess, D. S.

Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or Meropenem in Combination with Vancomycin

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2018-07-01

OAAI

Rutter, W. Cliff; Burgess, David S.

Influence of β-Lactam Infusion Strategy on Acute Kidney Injury

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2017-10-01

OAAI

Cotner, Sarah E.; Rutter, W. Cliff; Burgess, Donna R.; Wallace, Katie L.; Martin, Craig A.; Burgess, David S.

Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2017-04-01

OAAI

Crass, Ryan L.; Rutter, W. Cliff; Burgess, Donna R.; Martin, Craig A.; Burgess, David S.

Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime (vol 61, e02089-16, 2017)

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2017-04-01

OAAI

Rutter, W. Cliff; Cox, Jessica N.; Martin, Craig A.; Burgess, Donna R.; Burgess, David S.

Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2017-02-01

OAAI

Rutter, W. Cliff; Cox, Jessica N.; Martin, Craig A.; Burgess, Donna R.; Burgess, David S.

Development of New Antibacterials: A Laudable Aim, But What Is the Value? Response

CLINICAL INFECTIOUS DISEASES

IF7.3

2010-09-15

OAAI

Burgess, David S.; Slain, Douglas; Mohr, John; Wong-Beringer, Annie; Destache, Chris; Suda, Katie

Guideline-Concordant Antibiotic Use and Survival Among Patients With Community-Acquired Pneumonia Admitted to the Intensive Care Unit

CLINICAL THERAPEUTICS

IF3.6

2010-02-01

PREAI

Frei, Christopher R.; Attridge, Russell T.; Mortensen, Eric M.; Restrepo, Marcos I.; Yu, Yifan; Oramasionwu, Christine U.; Ruiz, Jessica L.; Burgess, David S.

研究方向